scholarly journals Topical Corticosteroids in Treatment of Atopic Dermatitis: An Overview of Their Current Status

2021 ◽  
pp. 1-20
Author(s):  
Kusha Sharma ◽  
Abhay Tharmatt ◽  
Shivali Salooria ◽  
Rashi Sharma ◽  
Neena Bedi
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Topical Steroid ◽  
Skin Barrier ◽  
Delivery Systems ◽  
Current Status ◽  
Topical Corticosteroids ◽  
Common Skin ◽  
Immunosuppressive Action

Atopic dermatitis (AD) is a common skin disease characterized by epidermal changes with immune regulatory abnormalities. The pathogenesis of AD involves skin barrier defects, genetic factors and immune deregulation. The AD therapy includes skin hydration, anti-inflammatory agents, antibacterial medications and treatment of pruritus. Currently, topical corticosteroids (TCs) are the most frequently used drugs for the treatment of AD due to their potent immunosuppressive action. However, TCs are associated with several local and systemic side effects. The topical steroid addiction and phobia are among the major challenges with TC therapy. Over the years, efforts are being made to reduce side effects which involve adjustment of dosing, minimizing use in vulnerable areas, avoiding prolonged drug usage and application of novel drug delivery systems. The present review provides an overview of the current and upcoming delivery systems of TCs along with novel approaches being employed to improve the drug delivery in the treatment of AD.

Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment

2020 ◽  
Vol 14 ◽  
Author(s):  
Emine Kahraman ◽  
Neriman Aydilek ◽  
Sevgi Güngör
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Drug Delivery Systems ◽  
Skin Permeation ◽  
Calcineurin Inhibitors ◽  
Chronic Inflammatory Disease ◽  
Delivery Systems ◽  
Drug Substances ◽  
Novel Drug

: Atopic dermatitis is a chronic inflammatory disease of the skin, which is characterized by itching, erythema and eczematous lacerations. It affects about 10 % of adults and approximately 15-20 % of children in the worldwide. As a result of genetic, immunologic and environmental factors, the disease manifests itself with impaired stratum corneum barrier and then immunological responses. Topical administration of corticosteroids and calcineurin inhibitors are currently used as the first strategy in the management of disease. However, they have low skin bioavailability and some side effects. The nano-carriers as novel drug delivery systems could overcome limitations of conventional dosage forms, owing to increment of poorly soluble drug' solubility, then its thermodynamic activity and consequently its skin permeation. Also, side effects of the drug substances on the skin could be reduced by the nano sized drug delivery systems, due to encapsulation of the drug in the nano-carriers and targeted drug delivery of drug substances to the inflammated skin areas. Thereby, there have been available a numerous of research studies and patents regarding use of the nano-carriers in the management of atopic dermatitis. This review focuses on the mechanism of disease and, developments on the nano-carrier based on novel drug release systems of in the management of atopic dermatitis.

scholarly journals Trends in Atopic Dermatitis—From Standard Pharmacotherapy to Novel Drug Delivery Systems

2019 ◽  
Vol 20 (22) ◽  
pp. 5659 ◽  
Author(s):  
Eliana B. Souto ◽  
João Dias-Ferreira ◽  
Jéssica Oliveira ◽  
Elena Sanchez-Lopez ◽  
Ana Lopez-Machado ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Drug Delivery Systems ◽  
Calcineurin Inhibitors ◽  
Skin Barrier ◽  
Delivery Systems ◽  
The Body ◽  
Barrier Dysfunction ◽  
First Line Therapy ◽  
Skin Delivery

Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.

Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy

2020 ◽  
Vol 21 (11) ◽  
pp. 1084-1098
Author(s):  
Fengqian Chen ◽  
Yunzhen Shi ◽  
Jinming Zhang ◽  
Qi Liu
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Therapeutic Index ◽  
Delivery Systems ◽  
Epigenetic Therapy ◽  
Cancer Therapies ◽  
Therapeutic Benefits ◽  
High Therapeutic Index

This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery systems with epigenetic therapy is a promising approach to reaching a high therapeutic index and minimizing the side effects.

Hydrogels for modified-release drug delivery systems

2021 ◽  
Vol 28 ◽  
Author(s):  
Aleksandra Zielińska ◽  
Piotr Eder ◽  
Lucas Rannier ◽  
Juliana C. Cardoso ◽  
Patrícia Severino ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Drug Delivery Systems ◽  
Search Strategy ◽  
Delivery Systems ◽  
Global Market ◽  
Modified Release ◽  
Safety And Efficacy ◽  
Area Of Interest ◽  
Release Drug

Abstract: Hydrogels for the modified-release drug delivery systems is a continuously growing area of interest for the pharmaceutical industry. According to the global market, the use of polymers in this area is projected to reach $31.4 million by 2027. This review discusses the recent advances and perspectives of hydrogel in drug delivery systems for oral, parenteral, nasal, topical, and ophthalmic. The search strategy did in January 2021, and it conducted an extensive database to identify studies published from January 2010 to December 2020.We described the main characteristic of the polymers to obtain an ideal hydrogel for a specific route of administration and the formulations that was a highlight in the literature. It concluded that the hydrogels are a set useful to decrease the number of doses, side effects, promote adhesion of patient and enhances the bioavailability of the drugs improving the safety and efficacy of the treatment.

Polymeric micelles as drug delivery systems in cancer: challenges and opportunities

Nanomedicine ◽  
2021 ◽  
Author(s):  
Swati Biswas
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Polymeric Micelles ◽  
Delivery Systems ◽  
Clinical Translation ◽  
Current Status ◽  
Chemotherapeutic Drugs ◽  
Challenges And Opportunities

Tweetable abstract Micelles are nanocarriers for hydrophobic chemotherapeutic drugs. This editorial discusses the current status of preclinical micellar research and sheds light on the possibility of their clinical translation.

Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art

2021 ◽  
Vol 17 (8) ◽  
pp. 1459-1485
Author(s):  
Mengyao Wang ◽  
Ying Qu ◽  
Danrong Hu ◽  
Ting Niu ◽  
Zhiyong Qian
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Nervous System ◽  
Drug Delivery Systems ◽  
Central Nervous System Lymphoma ◽  
Delivery Systems ◽  
Brain Diseases ◽  
Current Status ◽  
Great Promise ◽  
Antitumor Effects

Primary central nervous system lymphoma (PCNSL) is a rare but highly aggressive subtype of extra nodal non-Hodgkin lymphoma (NHL), which is confined in the central nervous system (CNS). Despite recent advancements in treatment options, the overall prognosis of PCNSL remains poor. Among many unfavorable factors affecting efficacy, inadequate drug delivery into the CNS is still the thorniest challenge. Blood-brain barrier (BBB) constitutes a significant impediment, restricting entry of most therapeutics to the brain. Nanotechnology has offered great promise for brain diseases, as various nano-based drug delivery systems (NDDSs) have been developed for delivery of theranostic agents in to the CNS. These drug delivery systems possess significant advantages, including good feasibility, reliable safety profile, excellent BBB penetration and potent antitumor effects. As for treatment of PCNSL, numerous well-developed BBB-crossing nano-based strategies can be applied with proper modifications and improvements. Some exquisitely designed NDDSs specific for PCNSL have shown great potential. In this review, we provide a summary on current status of diagnosis and treatment of PCNSL, followed by an overview of BBB-crossing strategies applied in management of PCNSL, both novel and wellestablished. Finally, challenges and future perspectives in this field are also discussed.

Dual-sensitive dual-prodrug nanoparticles with light-controlled endo/lysosomal escape for synergistic photoactivated chemotherapy

2021 ◽  
Author(s):  
Yubin Huang ◽  
Hongtong Lu ◽  
Shasha He ◽  
Qingfei Zhang ◽  
Xiaoyuan Li ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Clinical Application ◽  
Drug Delivery Systems ◽  
Controlled Drug Delivery ◽  
Delivery Systems ◽  
Chemotherapeutic Agents

The clinical application of conventional chemotherapeutic agents, represented by cisplatin, is limited by severe side effects. So, it is essential to explore more safer and controlled drug delivery systems for...

scholarly journals Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review

Polymers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1742 ◽  
Author(s):  
Olga Cegielska ◽  
Paweł Sajkiewicz
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Targeted Delivery ◽  
Drug Targets ◽  
Drug Delivery Systems ◽  
Release Kinetics ◽  
Controlled Drug Release ◽  
Drug Carriers ◽  
Delivery Systems ◽  
Drug Bioavailability

Each year, new glaucoma drug delivery systems are developed. Due to the chronic nature of the disease, it requires the inconvenient daily administration of medications. As a result of their elution from the eye surface and penetration to the bloodstream through undesired permeation routes, the bioavailability of active compounds is low, and systemic side effects occur. Despite numerous publications on glaucoma drug carriers of controlled drug release kinetics, only part of them consider drug permeation routes and, thus, carriers’ location, as an important factor affecting drug delivery. In this paper, we try to demonstrate the importance of the delivery proximal to glaucoma drug targets. The targeted delivery can significantly improve drug bioavailability, reduce side effects, and increase patients’ compliance compared to both commercial and scientifically developed formulations that can spread over the eye surface or stay in contact with conjunctival sac. We present a selection of glaucoma drug carriers intended to be placed on cornea or injected into the aqueous humor and that have been made by advanced materials using hi-tech forming methods, allowing for effective and convenient sustained antiglaucoma drug delivery.

scholarly journals Nanotechnology-Based Topical Drug Delivery Systems for Management of Dandruff and Seborrheic Dermatitis: An overview

2020 ◽  
Vol 29 (1) ◽  
pp. 12-32
Author(s):  
Lena M. Thomas ◽  
Abeer H. Khasraghi
Keyword(s):  
Drug Delivery ◽  
Patient Compliance ◽  
Therapeutic Efficacy ◽  
Drug Delivery Systems ◽  
Seborrheic Dermatitis ◽  
Delivery Systems ◽  
Drug Formulation ◽  
Topical Drug Delivery ◽  
Skin Disorders ◽  
Common Skin

Dandruff and seborrheic dermatitis (SD) are common skin disorders affecting the scalp and extending to other body sites in the case of SD. They are associated with pruritus and scaling, causing an esthetical disturbance in the population affected.   Treatment of such conditions involves using a variety of drugs for long terms, thus optimizing drug formulation is essential to improve therapeutic efficacy and patient compliance. Conventional topical formulations like shampoos and creams have been widely used but their use is associated with disadvantages. To overcome such effects, novel topical nanotechnology-based formulations are currently under investigation. In the following article, we highlight recently published formulation approaches used to improve topical dandruff/SD therapy

Sign in / Sign up

Export Citation Format

Share Document